Navigation Links
Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344
Date:3/6/2012

SAN DIEGO, March 6, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical testing for oncology drug candidate ME-344, the Company's lead mitochondrial inhibitor.

"I am extremely proud of our clinical operations and pre-clinical research teams in reaching this important milestone, less than seven months since our IND for ME-143 was approved by the FDA to begin clinical testing," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "We are prepared to initiate a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors immediately following approval by the FDA."

Marshall Edwards also announced that it has commenced dosing of the fourth cohort in its Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors. The Company expects to collect final safety and pharmacokinetic data from this trial by June.

"We continue to execute on the clinical development plan we set forth for our two most promising drug candidates," said Robert Mass, M.D., Chief Medical Officer of Marshall Edwards. "Now, as we await approval of our IND for ME-344 and near the completion of enrollment in our Phase I clinical trial of ME-143, we are diligently preparing for our Phase II trials."

Marshall Edwards owns exclusive worldwide rights to all of its drug candidates, including ME-143 and ME-344.

About ME-344
ME-344 is Marshall Edwards' lead mitochondrial inhibitor and an active metabolite of NV-128, a first-generation compound. Treatment of tumor cells with the Company's mitochondrial inhibitor compounds induces a rap
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock Conference
2. Marshall Edwards Announces Rights Offering to Stockholders
3. Marshall Edwards Adds $2 Million in Private Placement
4. Marshall Edwards Announces $2 Million Private Placement
5. Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
6. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
7. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
8. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
9. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
10. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
11. Marshall Edwards Announces Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Calif. , May 22, 2015 /PRNewswire/ ... the Company has commenced termination of its ... brodalumab with AstraZeneca (LON:AZN, STO:AZN and NYSE: ... inhibitor, is in development for patients with ... spondyloarthritis.  The decision was based on events ...
(Date:5/22/2015)... -- The Assistance Fund announces the addition of its ... for copay to individuals diagnosed with Melanoma. ... the Melanoma Copay Assistance Program to our portfolio of ... "With each additional program we are closer to achieving ... one is denied access to medications due to an ...
(Date:5/22/2015)... YORK , May 22, 2015  The ... of Zarxio (filgrastim-sndz) -- the first biosimilar product ... -- points toward growth in the contract ... The mainstream CMO industry is geared to the ... to produce major biopharmaceutical products. The healthcare market ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... ... ... ... ...
... ... ... , ... , , , , ...
Cached Medicine Technology:Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 2Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 3Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 4Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 5Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 6Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 7Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 8Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 9Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 10Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 11Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 12Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 13Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 14Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 15Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 16Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 17Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 18Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 19Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 20Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 21Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 22Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 23Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 24Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 25Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 26Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 27Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey) 28Pioneer(R) Surgical Technology, Inc. Launches Contact(R) Anterior Lumbar Plate March 1 2
(Date:5/24/2015)... May 24, 2015 Women's Excellence ... hair loss. Although it is unclear about the etiology ... environmental factors such as metabolism, nutritional deficiencies, thyroid abnormalities ... offer a comprehensive approach to evaluating the metabolic, nutritional ... they can help patients find a cause for their ...
(Date:5/24/2015)... May 24, 2015 EnviroLeather™ by ... “InkGard™ Plus” – a classic, rugged leather grain ... allowing difficult stains, including ink, to be easily ... colors suitable for corporate, healthcare, hospitality and education ... with EnviroLeather’s goal of developing products that are ...
(Date:5/24/2015)... Arizona (PRWEB) May 24, 2015 ... former Millennial Media strategy executive Jay Krihak as ... Medicx looks to ramp up its expertise and ... of the Pharmaceutical and Health sectors. , Krihak ... tech executive. Most recently, Krihak led sales planning ...
(Date:5/23/2015)... 2015 On May 13, Nithyananda Yoga ... youngster's yogic power learned through meditation and initiation at ... Bangalore, India. , Yogamaatha, a nine-year-old girl from North ... profile professionals attending the 2015 Business Advocacy Summit at ... blindfolded. , In a demonstration that lasted three ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 On May 16, ... MuckFest. The event was a 5k mud obstacle run that ... than 2 million people worldwide, and the reason we participated ... said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred percent ... Sclerosis Society.” , The event was not only attended by ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
... ... ... ... ...
... ... ... , ... , , ...
... 5, 2010) Components of the blood or hematopoietic system ... cell that gives rise to all the different kinds of ... ( www.bcm.edu ) in a report that appears in the ... ( www.cell.com/cell-stem-cell/ ) "While previous reports in ...
... Calculus Bovis compound preparation (ICCBco) in the treatment ... schistosomiasis as the experimental animal model, a research ... trial to observe pathological changes and pathological effect ... the lung tissue of portal hypertensive rabbits with ...
... novel immunotherapy appears to combat mesothelioma tumors , THURSDAY, ... the asbestos-related cancer mesothelioma is safe, according to a ... vaccine -- which infuses a patient,s own dendritic cells ... patients and found that it induced an immune T-cell ...
... ... ... ... ...
Cached Medicine News:Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 2Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 3Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 4Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 5Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 2Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 3Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 4Health News:Theory of single stem cell for blood components challenged 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Vaccine for Asbestos-Related Cancer Looks Safe 2Health News:Hill-Rom Announces Second Quarter 2010 Dividend 2
...
... This programmable system automates the ... (F)ISH procedures, and provides walk-away convenience ... low cost unit accepts a wide ... to use, and reduces hands-on time ...
... DiffSpin Slide Spinner for technique ... to wedge smears.,DiffSpin is a compact, ... for the preparation of uniformly distributed ... Complete with a start-up supply of ...
... deliver pulsed light over one smooth pulse ... (which may damage skin) that other technologies ... a chilled water supply through the StarLux ... is cooled to as low as 4 ...
Medicine Products: